A new cut point for Unfavorable Intermediate-Risk patients

The GPS assay stratifies unfavorable intermediate-risk patients into two distinct groups with highly differing long-term outcomes1


Unfavorable Intermediate-Risk Patients


GPS 40 wedge

orange person

May be candidates for less aggressive treatment

grey person

May be candidates for more aggressive treatment

 

The Oncotype DX GPS Test for Unfavorable Intermediate Risk Prostate Cancer

See how men with unfavorable intermediate-risk prostate cancer can be stratified into two distinct groups with highly differing long-term outcomes. Use the GPS assay to make informed treatment decisions based on a patient’s genomic risk.

 


Additional Resources

REFERENCES

  1. Cullen et al. Urology. 2020.
Making cancer care smarter.™
X

We may use cookies to improve your experience with our website and to provide you with more relevant content based on your interests. To learn more about what information we collect, how we use it, and how to manage cookies, review our Privacy Policy.